GT Biopharma Inc reports results for the quarter ended in June - Earnings Summary

GT Biopharma

11/08/2022 15:54

* GT Biopharma Inc  GTBP.OQ  reported a quarterly adjusted
loss
of 10 cents​​ per share for the quarter ended in June. The mean
expectation of two analysts for the quarter was for a loss of 17
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GT Biopharma Inc's reported EPS for the quarter was a loss
of 10
cents​.
    * The mean earnings estimate of analysts had risen by
about 45.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * GT Biopharma Inc shares had fallen by 4.0% this
quarter and
lost 5.9% so far this year.
    * The company reported a quarterly loss of $2.98 million.
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $17.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 02:54 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.17          -0.10          Beat
 Mar. 31 2022      -0.31          -0.17          Beat
 Dec. 31 2021      -0.21          -0.52          Missed
 Sep. 30 2021      -0.21          -0.19          Beat